Targeted therapy has transformed the treatment landscape of EGFR-mutated metastatic NSCLC, with Osimertinib firmly established as the standard first-line agent owing to its excellent systemic and intracranial efficacy, ease of administration, low risk of severe toxicity, and patient preferences for oral therapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.